[
  {
    "text": "1.23",
    "bbox": [
      111,
      80,
      142,
      92
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "\"TARA-002\" means the ArTara pharmaceutical product intended to be similar to or biosimilar to OK-432..",
    "bbox": [
      180,
      80,
      962,
      93
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.24",
    "bbox": [
      110,
      95,
      144,
      109
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "\"Territory\" means worldwide.",
    "bbox": [
      179,
      96,
      405,
      108
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "ARTICLE TWO",
    "bbox": [
      606,
      113,
      728,
      123
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "PROJECT",
    "bbox": [
      625,
      129,
      708,
      140
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "2.1 Performance of Project. The University and/or Principal Investigator together with ArTara and the CRO will conduct the Project in accordance",
    "bbox": [
      111,
      144,
      1000,
      157
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "with the Project Plan and will use all reasonable endeavors consistent with their expertise to successfully complete the Project. It is the goal of the",
    "bbox": [
      112,
      161,
      1000,
      173
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Project to use the Program Data as clinical support for Product Regulatory Filings and to gain approval to commercialize the Product for the",
    "bbox": [
      112,
      177,
      1000,
      189
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Indication in the Territory.",
    "bbox": [
      112,
      193,
      306,
      205
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "2.2 Project Plan. The Project Plan as approved by each of the Parties may be modified or amended only upon mutual agreement of each of the",
    "bbox": [
      110,
      207,
      1000,
      222
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Parties. The Project will consist of three phases:",
    "bbox": [
      110,
      225,
      472,
      236
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(a) Phase I: University and/or Principal Investigator will provide access to the Program Data to ArTara and the CRO at the",
    "bbox": [
      237,
      240,
      1000,
      253
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "University's facilities. ArTara and the CRO will be allowed to make complete copies of the original Program Data for the",
    "bbox": [
      273,
      257,
      1000,
      269
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "purposes of off-site data entry and storage, all as and only to the extent needed to support ArTara's efforts to accomplish the",
    "bbox": [
      271,
      272,
      1000,
      286
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "records for the Program Data at the University during normal business hours and at mutually agreeable times. University and",
    "bbox": [
      271,
      305,
      1000,
      317
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Principal Investigator will also provide to ArTara contact information for other participating investigators and research sites",
    "bbox": [
      273,
      321,
      1000,
      333
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "that have contributed data to the Program. University will retain all Program Data for the sooner to occur of a New Drug.",
    "bbox": [
      271,
      335,
      1000,
      351
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "understands that separate engagement agreements may be required by collaborating third party entities and associated",
    "bbox": [
      272,
      385,
      1000,
      397
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "principal investigators and University will assist ArTara in obtaining such agreements. It is understood that the goal of Phase",
    "bbox": [
      271,
      400,
      1000,
      414
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "I is a feasibility analysis of the Program Data to support Regulatory Filings in the United States.",
    "bbox": [
      271,
      416,
      988,
      429
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(b)",
    "bbox": [
      241,
      434,
      273,
      444
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": " Phase II: University recognizes that because of ArTara's unfamiliarity with the Program Data database, assistance from the",
    "bbox": [
      268,
      433,
      1000,
      445
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Principal Investigator and other research and medical employees of the University may from time to time be.",
    "bbox": [
      272,
      448,
      1000,
      461
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "needed for ArTara to query and analyze the Program Data database as needed to achieve successful presentation to",
    "bbox": [
      272,
      465,
      1000,
      476
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "applicable Regulatory Authorities and submission of Regulatory Filings. ArTara will endeavor to minimize University",
    "bbox": [
      274,
      481,
      1000,
      493
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "resources required during Phase II. The goal of Phase II will be to compile the Project Documentation..",
    "bbox": [
      271,
      497,
      1000,
      509
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(c)",
    "bbox": [
      240,
      514,
      263,
      524
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Phase III: CRO will convert Program Data to eCTD format for submission to Regulatory Authorities. University recognizes",
    "bbox": [
      270,
      513,
      1000,
      525
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "that ArTara may receive specific data requests from Regulatory Authorities in connection with ArTara's presentations of",
    "bbox": [
      272,
      528,
      1000,
      541
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Program Data to support Regulatory Filings. University will assist ArTara in responding to such requests for data or access to",
    "bbox": [
      273,
      545,
      1000,
      557
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "source data from Regulatory Authorities. ArTara agrees to notify University of such requests as soon as is practicable. The",
    "bbox": [
      271,
      560,
      1000,
      573
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "goal of Phase III will be filing of a BLA based on Project Documentation and response to Regulatory Authorities.",
    "bbox": [
      274,
      577,
      1000,
      589
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "4",
    "bbox": [
      663,
      609,
      673,
      618
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  }
]